1. Home
  2. EZRA vs ONCO Comparison

EZRA vs ONCO Comparison

Compare EZRA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reliance Global Group Inc. Common Stock

EZRA

Reliance Global Group Inc. Common Stock

N/A

Current Price

$0.21

Market Cap

2.4M

Sector

Finance

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.76

Market Cap

755.3K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZRA
ONCO
Founded
2013
2018
Country
United States
United States
Employees
64
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
755.3K
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EZRA
ONCO
Price
$0.21
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.8M
12.6M
Earning Date
05-14-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.05
52 Week High
$0.39
$7.65

Technical Indicators

Market Signals
Indicator
EZRA
ONCO
Relative Strength Index (RSI) 55.30 43.33
Support Level $0.20 $0.51
Resistance Level $0.22 $0.95
Average True Range (ATR) 0.02 0.80
MACD 0.00 -0.11
Stochastic Oscillator 75.21 1.47

Price Performance

Historical Comparison
EZRA
ONCO

About EZRA Reliance Global Group Inc. Common Stock

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: